Heron Therapeutics, Inc. Expected to Post FY2017 Earnings of ($3.32) Per Share (HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX) – Cantor Fitzgerald issued their FY2017 earnings per share estimates for Heron Therapeutics in a research report issued on Monday. Cantor Fitzgerald analyst L. Chen expects that the biotechnology company will post earnings per share of ($3.32) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.
Several other research analysts also recently commented on the company. Zacks Investment Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 7th. Aegis reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, March 21st. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Friday, May 12th. Cowen and Company reaffirmed a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a report on Friday, May 26th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Heron Therapeutics in a report on Monday, April 10th. Two research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $34.50.
Shares of Heron Therapeutics (NASDAQ HRTX) opened at 13.85 on Wednesday. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $24.00. The company has a 50-day moving average price of $14.32 and a 200-day moving average price of $14.12.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.06. The company had revenue of $3.63 million during the quarter, compared to analyst estimates of $1.96 million.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc raised its position in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,098 shares during the period. Venturi Wealth Management LLC acquired a new position in Heron Therapeutics during the first quarter valued at $161,000. Pacad Investment Ltd. acquired a new position in Heron Therapeutics during the fourth quarter valued at $155,000. Old West Investment Management LLC acquired a new position in Heron Therapeutics during the first quarter valued at $206,000. Finally, Highbridge Capital Management LLC raised its position in Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 252 shares during the period.
In other Heron Therapeutics news, VP Kimberly Manhard sold 21,542 shares of Heron Therapeutics stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $15.33, for a total transaction of $330,238.86. Following the transaction, the vice president now directly owns 5,250 shares of the company’s stock, valued at approximately $80,482.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.31% of the stock is currently owned by insiders.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.